FY2026 Earnings Forecast for IDXX Issued By Leerink Partnrs

Key Points

• Leerink Partners has raised its FY2026 earnings estimate for IDEXX Laboratories to $14.31 per share from a previous forecast of $14.29, surpassing the current consensus estimate of $11.93.
• Multiple analysts have increased their price targets for IDEXX stock, with Leerink Partners setting a target of $600 and JPMorgan increasing theirs to $675.
• Insiders have sold a total of $34 million in company stock over the last ninety days, with a notable sale by EVP Michael Lane resulting in a 54% decrease of his position in IDEXX.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2026 EPS estimates for shares of IDEXX Laboratories in a research note issued on Friday, August 15th. Leerink Partnrs analyst D. Clark now forecasts that the company will earn $14.31 per share for the year, up from their prior forecast of $14.29. The consensus estimate for IDEXX Laboratories' current full-year earnings is $11.93 per share.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm earned $2.44 earnings per share. The business's quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS.

A number of other analysts have also issued reports on the stock. Piper Sandler reissued a "neutral" rating and issued a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. BTIG Research increased their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 4th. Finally, Morgan Stanley increased their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $649.44.

IDEXX Laboratories Stock Up 1.8%

Shares of NASDAQ IDXX traded up $11.3980 during mid-day trading on Monday, reaching $644.4480. The company had a trading volume of 185,268 shares, compared to its average volume of 720,769. The stock has a fifty day moving average of $567.48 and a two-hundred day moving average of $492.73. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a market capitalization of $51.56 billion, a price-to-earnings ratio of 53.72, a PEG ratio of 4.14 and a beta of 1.49. IDEXX Laboratories has a 12-month low of $356.14 and a 12-month high of $688.12.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the transaction, the executive vice president owned 18,007 shares in the company, valued at $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the transaction, the executive vice president owned 11,287 shares in the company, valued at approximately $7,336,098.52. This trade represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,870 shares of company stock valued at $32,877,757 in the last ninety days. 0.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. MorganRosel Wealth Management LLC acquired a new position in IDEXX Laboratories during the first quarter valued at approximately $26,000. Opal Wealth Advisors LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $29,000. WealthCollab LLC acquired a new position in IDEXX Laboratories during the second quarter valued at approximately $30,000. Colonial Trust Co SC grew its holdings in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after purchasing an additional 30 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.